Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126282 · ClinicalTrials.gov registry record · NA
A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT00126282: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00126282 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00126282, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study examines the efficacy of the medication D-Cycloserine in the reduction of obsessions and compulsions in individuals with obsessive-compulsive disorder (OCD). All study participants will receive Exposure and Response Prevention, a common form of behavior therapy for individuals with OCD. Half (50%) of the participants will be randomly assigned to the placebo condition and the other half (50%) will be randomly assigned to receive D-Cycloserine. Because all participants will receive 10 sessions of behavior therapy, all participants are expected to improve from this treatment.
Interventions
- DRUG D-Cycloserine
- BEHAVIORAL behavior therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-12 |
| Est. Completion | 2007-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126282
The ClinicalTrials.gov registry entry for NCT00126282 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which D-Cycloserine is the first listed.
NCT00126282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126282 about?
NCT00126282 is a clinical study titled "A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder". This study examines the efficacy of the medication D-Cycloserine in the reduction of obsessions and compulsions in individuals with obsessive-compulsive disorder (OCD). All study participants will receive Exposure and Response Prevention, a common form of behavior therapy for individuals with OCD. H...
What is the current status of trial NCT00126282?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2003-12. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00126282?
The interventions under investigation include: D-Cycloserine (DRUG), behavior therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00126282?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.